Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Breast Cancer / Mammacarcinoma & Drugs/Treatments

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

The management of Breast Cancer / Mammacarcinoma lacks specific non-invasive biomarkers. These are needed for early diagnosis.
Vietri et al. 2021 Int J Oncol. 59:

Unfortunately, treatments often fail due to the development of drug resistance, the underlying mechanisms of which remain unclear.
Liu et al. 2020j Future Oncology 16: 2863–2878

see also:
Breast Cancer / Mammacarcinoma (BRCA m) & Drugs/Treatments
Breast Cancer / Mammacarcinoma (HR+) (ER+) & Drugs/Treatments
[Breast cancer / Mammacarcinoma (HER2+) & Drugs/Treatments](brain://PWhXpTZ…

References (Sources)

A review of FDA approved drugs and their formulations for the treatment of breast cancer
Chaurasia et al. 2023 Front Pharmacol 14: 1184472
Review
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Sparano et al. 2019 N Engl J Med 380: 2395-2405
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Korde et al. 2021
Optimizing treatment strategy in early breast cancer: less is more, or more is better?
Morganti & Curigliano 2019 Current Opinion in Oncology 31: 469-471
Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer
Darden et al. 2019
Tucidinostat + exemestane for postmenopausal pts with advanced, hormone receptor-positive mammacarcinoma (ACE): a randomised, double-blind, placebo-controlled, phase III trial
Jiang et al. 2019 Lancet Oncology 20: 806-815
US Food and Drug Administration approval overview in metastatic breast cancer
Cortazar et al. 2012 J Clin Oncol 30(14): 1705-11
Review

AI Chat

7/1/2026

Chat with our artificial intelligence: